Contract development, manufacturing and packaging organization, Quay Pharma, has entered into an agreement with drug discovery and development company, Redx Pharma, to manufacture its new cancer treatment drug. The new Porcupine inhibitor has the potential to tackle hard-to-treat cancers such as pancreatic, gastric and biliary. Quay will formulate the capsules, which will be administered during the drug’s first-in-human studies early 2017. The new treatment will have the potential for pati...